APIs of Zolmitriptan

  • Author:Ray Dean
  • Release on :2016-11-13

Zolmitriptan is a selective 5-HTIB / ID receptor agonist. By stimulating intracranial blood vessels (including arteriovenous anastomosis) and the sympathetic nervous system on the 5-HTIB / ID receptor, causing intracranial vasoconstriction and inhibition of pre-inflammatory neuropeptide release. For the treatment of adult or non-aura migraine. Zolmitriptan absorbed rapidly after oral administration. 1 hour peak plasma concentration of up to 75%, followed by plasma concentration of 4 to 6 hours. The average absolute bioavailability of the parent compound was about 40%.


Zolmitriptan mainly through the liver biotransformation, and metabolites excreted from the urine. The three main metabolites are: indoleacetic acid (the main metabolite in plasma and urine), N-oxide and N-demethyl metabolite. N-demethyl metabolites are active and other metabolites are inactive. The plasma concentration of the N-demethyl metabolite is approximately half that of the parent drug; therefore, it is expected to contribute to the therapeutic effect of this product. More than 60% of the oral single dose is excreted in the urine (mainly indoleacetic acid metabolites), and about 30% of the parent compound by the prototype excreted by feces. The renal clearance rate of this product is greater than the glomerular filtration rate, suggesting the presence of renal tubular secretion.


Hubei Ocean Biotech Co., Ltd, a leading professional chemical industry enterprise with integrating production and trade for global valued customer with our superior quality and reliable cooperation. Should you have any interest in our APIs Pharma Products, welcome to take view at our site and be feel free to contact me.